Contribution: Industrial Research Assistance Program – Contributions to Firms
London Pharmaceuticals and Research Corporation
$73,880.00
Development of soluble cannabinoids for nutraceutical and medicinal use.
FY 2023-24 · 2023-06-01
Summary
The presented research program aims at developing water soluble derivatives of cannabinoids and their stable product formulations for health and medicinal applications. London Research and Pharmaceuticals Corporation (LRPC) developed a strategy to optimize the physicochemical and pharmacological properties of cannabinoids via providing new methods to convert cannabinoids (CBD) into fully soluble and stable products (Patent # US62/970,764) that are deliberately designed to impart specific properties that will be readily translated into nutraceuticals + pharmaceuticals and strengthen the health + wellness cannabis market where no fully soluble cannabinoids are known. The proposed project aims at scaling up the synthesis process and designing a validated manufacturing process of LRPC-soluble CBD. This is a major discovery with wide-reaching global implications including significant revenue potential across several multi-billion-dollar industries where LRPC would be first to market.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Location
London|London, Ontario, Canada
Recipient Type
For-profit organization
Business Number
715091286
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
As published
Agreement End Date
2023-09-08
Agreement Number
1008129
Agreement Start Date
2023-06-01
Agreement Title
Development of soluble cannabinoids for nutraceutical and medicinal use.
Agreement Title (French)
Développement de cannabinoïdes solubles à usage nutraceutique et médicinal.
Agreement Type
Contribution
Agreement Value
$73,880.00
Amendment Number
0
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
The presented research program aims at developing water soluble derivatives of cannabinoids and their stable product formulations for health and medicinal applications. London Research and Pharmaceuticals Corporation (LRPC) developed a strategy to optimize the physicochemical and pharmacological properties of cannabinoids via providing new methods to convert cannabinoids (CBD) into fully soluble and stable products (Patent # US62/970,764) that are deliberately designed to impart specific properties that will be readily translated into nutraceuticals + pharmaceuticals and strengthen the health + wellness cannabis market where no fully soluble cannabinoids are known. The proposed project aims at scaling up the synthesis process and designing a validated manufacturing process of LRPC-soluble CBD. This is a major discovery with wide-reaching global implications including significant revenue potential across several multi-billion-dollar industries where LRPC would be first to market.
Description (French)
Le programme de recherche présenté vise à développer des dérivés hydrosolubles de cannabinoïdes et leurs formulations de produits stables pour des applications sanitaires et médicinales. London Research and Pharmaceuticals Corporation (LRPC) a mis au point une stratégie visant à optimiser les propriétés physicochimiques et pharmacologiques des cannabinoïdes en proposant de nouvelles méthodes pour convertir les cannabinoïdes (CBD) en produits stables et entièrement solubles (brevet # US62/970,764) qui sont délibérément conçus pour conférer des propriétés spécifiques qui seront facilement traduites en produits nutraceutiques et pharmaceutiques et renforceront le marché du cannabis pour la santé et le mieux-être où aucun cannabinoïde entièrement soluble n’est connu. Le projet proposé vise à étendre le processus de synthèse et à concevoir un processus de fabrication validé du CBD soluble dans le LRPC. Il s’agit d’une découverte majeure ayant des implications mondiales de grande envergure, y compris un potentiel de revenus important dans plusieurs industries de plusieurs milliards de dollars où la LRPC serait la première à être commercialisée.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
London North Centre
Federal Riding (French)
London-Centre-Nord
Federal Riding Number
35052
NAICS Code
541710
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
715091286
Recipient City
London|London
Recipient Country
CA
Recipient Legal Name
London Pharmaceuticals and Research Corporation
Recipient Operating Name
London Research and Pharmaceuticals
Recipient Postal Code
N6G 4X8
Recipient Province or Territory
ON
Recipient Type
F
Reference Number
172-2023-2024-Q2-1008129
